BIO: Provenge gets mixed reception
This article was originally published in Scrip
Executive Summary
Dendreon's Provenge (sipuleucel-T), the first therapeutic cancer vaccine to be approved in the US by the FDA, met with varied reactions at this year's BIO International Convention.